ABSTRACT Thirty patients with stable chronic airflow obstruction receiving regular bronchodilator treatment were studied to determine whether the level of bronchial responsiveness, transfer factor for carbon monoxide (TLCO), or the mechanical properties of the lung predicted a bronchodilator response to oral corticosteroid treatment. Before treatment mean (SD) FEV, was 48% (16%) of the predicted value (% pred); the geometric mean concentration of methacholine required to produce a 20% fall in FEV, (PC20) was 0A44 (range 0 07-3 32) mg/ml; and TLCO was 59% (21 %) predicted. The exponential constant (k) defining the shape of the static volume-pressure curve was 146% (66%) predicted and pulmonary conductance relative to predicted lung volume at a transpulmonary pressure of 5 cm H20 (sGL5) was 72% (37%) predicted. After prednisolone treatment (0-6 mg kg-' day-' for two weeks) FEV1 increased by 8% (19%) (p < 0 05) and daily mean peak flow (PEF) by 3% (10%) (p < 0 01) over pretreatment values. Three patients had an increase in FEV1 of more than 30%, two of whom had sputum eosinophilia (p < 0 05). The three were among the 13 patients with a reduced sGL5. The increase in FEV1 did not correlate with initial PC20 (r = -0'16), k (r = -0 12), or TLCO (r = -0 14). Thus measurements ofbronchial responsiveness, lung distensibility, and TLCO did not predict corticosteroid response in patients with stable chronic airflow obstruction. Patients with sputum eosinophilia or reduced pulmonary conductance may be more likely to respond.
Introduction
In a variable proportion of individuals with chronic airflow obstruction FEV, increases after optimal treatment with bronchodilators and systemic corticosteroids.'-" Patients' characteristics, such as the acute response to a bronchodilator,' 2 " increased blood or sputum eosinophil count,23 variability of symptoms and ventilatory capacity,3 and a personal or family history of allergy,4 have been associated with responsiveness to corticosteroids but none allows accurate prediction of response. A trial of treatment with corticosteroids remains the only definitive method of identifying subjects who will respond." ' A means of predicting a response to corticosteroids would be useful.
Chronic airflow obstruction may be due to intrinsic airway narrowing from inflammation, fibrosis of airway walls, or smooth muscle hypertrophy; to loss of airway support resulting from emphysema; or to a combination of mechanisms.'4 Corticosteroids might be expected to improve airflow obstruction caused by intrinsic airway narrowing but to have no effect on that due to emphysema. It may therefore be possible to predict corticosteroid responsiveness from measurements that reflect these aspects of lung function. Intrinsic airway narrowing would be expected to cause a reduction in pulmonary conductance with normal lung distensibility'5 16; transfer factor (diffusing capacity) for carbon monoxide (TLCO) iS usually reduced in emphysema, '7 and normal or increased with airflow obstruction due to airway disease. Nonspecific bronchial responsiveness is variably increased in asthma and in chronic bronchitis. '8 In asthma it is related to disease severity and treatment requirements'9 but its significance in chronic bronchitis is less clear.20"2 As bronchial responsiveness is an indicator of Bronchial responsiveness, lung mechanics, gas transfer, and steroid response in chronic airflow obstruction 917 variability of airflow obstruction it might be expected to predict corticosteroid responsiveness.
We have therefore investigated whether patients with chronic airflow obstruction who respond 'to corticosteroids can be characterised as having evidence of intrinsic airway narrowing-that is, decreased pulmonary conductance relative to lung elastic recoil pressure, decreased FEV, in the presence of relatively normal TLCO and pulmonary distensibility, and/or increased bronchial responsiveness. Thus we measured the mechanical properties of the lung and non-specific bronchial responsiveness in patients with stable chronic airflow obstruction and related these measures to the change in FEV, after a course of systemic corticosteroid treatment. We also determined atopy on the basis of prick skin tests with common allergens and examined sputum and blood for eosinophils.
Methods

SUBJECTS
Patients with chronic airflow obstruction attending outpatient clinics at the Sir Charles Gairdner Hospital were eligible for inclusion in the study if a trial of steroids was thought indicated by their attending physician and if (1) forced expiratory volume in one second (FEVY) was less than 80% of the predicted value' while they were taking the beta2 adrenoreceptor agonist salbutamol (200 pg from a metered dose inhaler or 5 mg by nebuliser at least four times a day) and maximum tolerated doses of slow release theophylline for two weeks; (2) airflow obstruction was stable with no change in symptoms over the previous three months; (3) . A weal diameter of 3 mm or more measured 15 minutes after the skinprick was considered a positive result. Subjects with one or more positive results were classified as atopic. A sputum sample was examined for eosinophils. Venous blood was collected for estimation of a, antitrypsin concentration and determination of phenotype, total and differential white blood cell count, and serum theophylline concentration. Sputum eosinophilia was defined as a differential eosinophil count of greater than 5% and peripheral blood eosinophilia as an absolute count ofgreater than 04 eosinophils x 109/l.
After the initial assessment patients measured peak expiratory flow (PEF), using a mini Wright peak flow meter (Clement Clarke, London), each morning and evening, before and 30 minutes after their usual dose of aerosol bronchodilator. On each occasion they recorded the best of three attempts and from the four readings each day the daily mean peak flow rate was calculated.
Maximum Bronchial responsiveness was measured by using continuous aerosol delivery during tidal breathing. '9 The test was performed 48 hours after the last use of slow release theophylline and at least six hours after the last use of inhaled beta agonist drugs. Subjects inhaled aerosols of buffered normal saline followed by doubling concentrations of histamine in saline, starting at 0-06 mg/ml, until FEV, fell by 20% from the post-saline level. The concentration of histamine that caused a 20% fall in FEV, (PC20) was obtained from the dose-response curve by linear interpolation of the last two points.
PROTOCOL
On entry into the study patients completed a questionnaire, had a clinical assessment, and began daily measurements of peak expiratory flow (which were continued throughout the four week study period). For the first two weeks patients used regular bronchodilator treatment and then added oral prednisolone for a further two weeks. Tests of pulmonary function (before and after bronchodilator) were performed immediately before and after the period of prednisolone treatment.
Prednisolone, 0'6 mg kg-' day-'(35-60 mg/day), was given as a single dose each morning for two weeks. Compliance with treatment was assessed by Three patients (baseline FEV, 0 73, 0-63, and 1-13 litres) had an increase in FEV, ofmore than 30% from the initial value after prednisolone (fig 1) . These patients were among the 13 subjects with an.sGL, less than 005 s`cm H20-' (fig 2c) . This pattern was observed whether conductance was expressed as measured GLS or the GL-P,,L slope. Change in FEV, was not related to initial PC2., k, sGL3, or TLCO (fig 2) .
Multiple regression analysis showed no relation between PC2,,, k, TLCO or sGL, and either the FEV, or PEF response to prednisolone. The patients with more than a 30% response were not distinguishable on the basis of a past history of asthma (two "Yes", one "No"), chronic bronchitis (two "Yes," one "No"), serum IgE, prick skin test responses, or blood eosinophilia and none of the three had a greater than 20% response to inhaled bronchodilators at the start of the study. In the two whose sputum was available for examination eosinophil numbers were increased (80% and 20% of white cells). This was more common than in patients with less than a 30% response to steroids (three of 22; x2 = 4.43, p < 0-05).
Discussion
In this group of 30 patients with stable severe chronic airflow obstruction only three patients achieved an increase in FEV, of > 30% after a course of systemic corticosteroids, a response rate similar to that found in other studies.`' The three subjects who responded to corticosteroids were among the thirteen patients who had a sGL, <0'05 s:' cm H20-', indicating intrinsic airway narrowing. This suggests that only a minority of subjects with intrinsic airway narrowing will respond to steroids.
Various measures have been associated with a response to systemic corticosteroids previously,'4" but this is the first study to use the relation between GL and P,L to define the presence of intrinsic airway disease and examine its value in predicting the response to treatment with corticosteroids. The results suggest that the measurement has a low predictive value. Further, there was no significant association between change in FEV, (or PEF) with corticosteroid treatment and lung distensibility, gas transfer, or bronchial responsiveness to histamine.
Patients with features that may predict variable airflow obstruction such as a personal or family history of asthma, blood eosinophilia, and a greater than 15% response to a bronchodilator were included in the study. In some but not all studies these characteristics have been associated with a response to corticosteroids.' 411 In the present study sputum eosinophilia (> 5% white cells) was more common in those who responded to prednisolone, although there was substantial overlap with those who did not respond. Bronchial responsiveness, lung mechanics, gas transfer, and steroid response in chronic airflow obstruction 921 chial responsiveness and the response to corticosteroids has been previously reported.9t0 Gove et al, using methods similar to ours, found that subjects whose FEV, increased by more than 20% with prednisolone had an almost 10 fold lower PCI, (that is, greater bronchial responsiveness) than subjects with an increase of20% or less, but the differences were not significant.'°T he implication ofthis and previous studies is that it is difficult to predict from clinical and functional characteristics which patients with chronic airflow obstruction will respond to corticosteroid treatment. Our study suggests that patients who respond to corticosteroids are more likely to have sputum eosinophilia and reduced pulmonary conductance, but these measurements have a low predictive value. Assessment ofintrinsic airway narrowing and measurements of bronchial responsiveness are unlikely to help select patients who will respond to corticosteroids. The practice of giving a course of steroids to all patients with symptoms attributable to chronic airflow obstruction is likely to continue,'2"3 despite the low rate of response and the risk of side effects, albeit small with the recommended dose and duration of treatment. Eliasson and colleagues' have questioned the value of corticosteroids in these patients because the response is so small and obtained by a dose of prednisolone that is unacceptable for long term treatment. More information is required on the long term benefits ofa short term response to steroids in terms of maintenance of improved lung function, reduced morbidity from chronic airflow limitation, and improved survival. 
